博瑞医药在美国糖尿病协会第85届科学会议发布多项临床前成果

Core Insights - 博瑞医药 announced the results of two Phase II clinical studies for its dual-target agonist BGM0504 and preclinical results for the new Amylin BGM1812 at the 85th Scientific Sessions of the American Diabetes Association [2] - BGM0504 is a GLP-1/GIP receptor dual agonist that shows potential for treating metabolic diseases, including blood sugar control, weight loss, and non-alcoholic fatty liver disease (NASH) [2] - The drug is currently undergoing Phase III clinical trials in China for weight management and type 2 diabetes, with over 1,000 patients treated, demonstrating excellent efficacy and safety [2] Clinical Study Results - The completed Phase II trial CTR202232464 in China showed that BGM0504 demonstrated comprehensive potential in glycemic control and other related benefits in type 2 diabetes patients, with preliminary efficacy appearing superior to semaglutide [3] - Adverse events during treatment were mostly mild (grade 1-2), with common gastrointestinal reactions being transient diarrhea, nausea, and bloating, and no occurrences of hypoglycemia or other unexpected adverse reactions [3] - Another Phase II trial CTR20233198 in overweight or obese non-type 2 diabetes subjects indicated significant weight management potential and comprehensive metabolic risk benefits for BGM0504 [3] Expert Commentary - Professor Ji Linong from Peking University People's Hospital stated that BGM0504 shows significant preliminary efficacy and good tolerability, making it a strong candidate for further development in type 2 diabetes treatment [4] - BGM1812, designed using AI/ML, exhibits strong and ultra-long-lasting effects, with potential for weekly oral administration [4] - Initial data from the DIO model suggests that the combination of BGM1812 and BGM0504 outperforms combinations of semaglutide with Cagrilintide or Amycretin in terms of weight loss sustainability and efficacy [4] - The chairman of 博瑞医药, 袁建栋, emphasized the international first-tier potential of BGM0504 for treating type 2 diabetes and obesity, along with the development value of BGM1812 [4]